Insider · CIK 0001778279
Emily Luisa Hill
cfoofficer
Files at REPL (Replimune Group, Inc.). First filing May 22, 2025, latest Aug 19, 2025.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 2
$0 bought, $70k sold
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
REPL: Replimune Group, Inc.
REPLOct 9, 2026 · close 13.42
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 29Weak | REPLsell Replimune Group, Inc. | $49k 9,154 shares | -6% | +98% from low-63% from high | |
| 37Weak | Replimune Group, Inc. | $20k 2,535 shares | -2% | +33% from low-38% from high |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 19, 2025 | REPL Replimune Group, Inc. | AGrant or award Common Stock | +60,000 | $0.00 | $0 | 194,368 | Dec 19, 2025 |
| Aug 15, 2025 | REPL Replimune Group, Inc. | SOpen-market sale Common Stock | -9,154 | $5.37 | $49k | 134,368 | Aug 19, 2025 |
| May 20, 2025 | REPL Replimune Group, Inc. | SOpen-market sale Common Stock | -2,535 | $8.05 | $20k | 143,522 | May 22, 2025 |
| Apr 1, 2025 | REPL Replimune Group, Inc. | AGrant or award Common Stock | +45,000 | $0.00 | $0 | 146,057 | Apr 3, 2025 |
| Apr 1, 2025 | REPL Replimune Group, Inc. | AGrant or award Employee Stock Option (right to buy)derivative | +67,500 | $0.00 | $0 | 67,500 | Apr 3, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.